Present status of modified hemoglobin as blood substitutes and oral therapy for end stage renal failure using artificial cells containing genetically engineered cells.
Artificial cell or bioencapsulation has been developed for use in bioartificial organs, drug delivery, blood substitutes, and other areas. Recent rapid advances in modified hemoglobin blood substitutes have resulted in advance stages of Phase III clinical trials. Another area of use is in oral therapy, using artificial cells microencapsulated with genetically engineered cells for use in end stage renal failure and other conditions.
Chang
T M
TM
Faculty of Medicine, McGill University, Montreal, Quebec, Canada. artcell@med.mcgill.ca
D000284:Administration, Oral; D001187:Artificial Organs; D001802:Blood Substitutes; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006454:Hemoglobins / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*
D001802:Blood Substitutes; D006454:Hemoglobins